OncoMatch/Clinical Trials/NCT06749860
Disitamab Vedotin in Combination with Tislelizumab and Bevacizumab in a Phase II Clinical Study of Locally Advanced or Metastatic Non-small Cell Lung Cancer with HER2 Mutation/amplification/expression
Is NCT06749860 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Disitamab Vedotin + tislelizumab + bevacizumab for lung cancer.
Treatment: Disitamab Vedotin + tislelizumab + bevacizumab — The goal of this clinical trial is to learn ifDisitamab Vedotin in combination with tislelizumab and bevacizumab can treat in locally advanced or metastatic non-small cell lung cancer patients with HER2 mutation/amplification/expression. The main questions it aims to answer are: 1. objective response rate; 2. Progression-Free Survival; 3. Overall Survival; 4. Disease Control Rate; 5. Duration of Response.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Small Cell Lung Carcinoma
Biomarker criteria
Required: PD-L1 (CD274) any tested (testing required; no eligibility threshold specified)
Required: HER2 (ERBB2) amplification
Required: HER2 (ERBB2) expression (ihc 1+, 2+, or 3+) (ihc 1+, 2+, or 3+)
Required: HER2 (ERBB2) mutation
Disease stage
Required: Stage IIIB, IIIC, IV
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: HER2 antibody
Prior treatment with HER2 antibodies
Cannot have received: antibody-drug conjugate
Prior treatment with ... antibody-drug conjugates
Lab requirements
Blood counts
ANC >= 1.5×10^9/L; platelets >= 100×10^9/L; hemoglobin >= 90g/L (no transfusion in past 7 days)
Kidney function
serum creatinine <= 1.5x ULN
Liver function
total bilirubin <= 1.5x ULN; AST/ALT <= 2.5x ULN (<= 5x ULN with liver metastasis)
Adequate hematologic function ... Adequate liver function ... Adequate renal function ...
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify